Cell cycle inhibitors for the treatment of NSCLC

Marina Shcherba, Yuanxin Liang, David Fernandes, Roman Perez-Soler, Haiying Cheng

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Introduction: Lung cancer remains to be the leading cause of cancer-related death worldwide. Treatment of lung cancer still poses a significant challenge. Cell cycle is a tightly integrated process and is frequently aberrant in lung cancer. Cell cycle inhibitors have emerged as novel therapeutics, in anticipation of overcoming the unrestricted cell division and growth in lung cancer. Areas covered: In this article, we first address the potential roles of cell cycle proteins and cell cycle deregulation in the development of lung cancer. The review then provides an overview for several major categories of cell cycle inhibitors with particular attention to their tolerability and disease control in early phases of lung cancer trials. Expert opinion: Targeted agents against different components of cell cycle regulation, such as cyclin-dependent kinase, polo-like kinase, checkpoint kinase and aurora kinase, are currently in clinical development for lung cancer management. Their clinical benefits remain to be defined. When evaluated as single agents in lung cancer, cell cycle inhibitors are often associated with limited clinical activity and tolerable toxicities. The key challenges in the drug development are to understand resistance mechanisms and to identify predictive biomarkers that can potentially guide patient selection and optimize the utility of these targeted inhibitors.

Original languageEnglish (US)
Pages (from-to)991-1004
Number of pages14
JournalExpert Opinion on Pharmacotherapy
Volume15
Issue number7
DOIs
StatePublished - 2014

Fingerprint

Lung Neoplasms
Cell Cycle
Phosphotransferases
Aurora Kinases
Cell Cycle Proteins
Cyclin-Dependent Kinases
Expert Testimony
Cell Division
Patient Selection
Biomarkers
Growth
Pharmaceutical Preparations
Neoplasms

Keywords

  • Aurora kinase
  • Cell cycle inhibitor
  • Cyclin-dependent kinase
  • Lung cancer
  • Polo-like kinase

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Cell cycle inhibitors for the treatment of NSCLC. / Shcherba, Marina; Liang, Yuanxin; Fernandes, David; Perez-Soler, Roman; Cheng, Haiying.

In: Expert Opinion on Pharmacotherapy, Vol. 15, No. 7, 2014, p. 991-1004.

Research output: Contribution to journalArticle

Shcherba, Marina ; Liang, Yuanxin ; Fernandes, David ; Perez-Soler, Roman ; Cheng, Haiying. / Cell cycle inhibitors for the treatment of NSCLC. In: Expert Opinion on Pharmacotherapy. 2014 ; Vol. 15, No. 7. pp. 991-1004.
@article{33d30e686f9f4bdcbe0a2d1416fb1ea6,
title = "Cell cycle inhibitors for the treatment of NSCLC",
abstract = "Introduction: Lung cancer remains to be the leading cause of cancer-related death worldwide. Treatment of lung cancer still poses a significant challenge. Cell cycle is a tightly integrated process and is frequently aberrant in lung cancer. Cell cycle inhibitors have emerged as novel therapeutics, in anticipation of overcoming the unrestricted cell division and growth in lung cancer. Areas covered: In this article, we first address the potential roles of cell cycle proteins and cell cycle deregulation in the development of lung cancer. The review then provides an overview for several major categories of cell cycle inhibitors with particular attention to their tolerability and disease control in early phases of lung cancer trials. Expert opinion: Targeted agents against different components of cell cycle regulation, such as cyclin-dependent kinase, polo-like kinase, checkpoint kinase and aurora kinase, are currently in clinical development for lung cancer management. Their clinical benefits remain to be defined. When evaluated as single agents in lung cancer, cell cycle inhibitors are often associated with limited clinical activity and tolerable toxicities. The key challenges in the drug development are to understand resistance mechanisms and to identify predictive biomarkers that can potentially guide patient selection and optimize the utility of these targeted inhibitors.",
keywords = "Aurora kinase, Cell cycle inhibitor, Cyclin-dependent kinase, Lung cancer, Polo-like kinase",
author = "Marina Shcherba and Yuanxin Liang and David Fernandes and Roman Perez-Soler and Haiying Cheng",
year = "2014",
doi = "10.1517/14656566.2014.902935",
language = "English (US)",
volume = "15",
pages = "991--1004",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - Cell cycle inhibitors for the treatment of NSCLC

AU - Shcherba, Marina

AU - Liang, Yuanxin

AU - Fernandes, David

AU - Perez-Soler, Roman

AU - Cheng, Haiying

PY - 2014

Y1 - 2014

N2 - Introduction: Lung cancer remains to be the leading cause of cancer-related death worldwide. Treatment of lung cancer still poses a significant challenge. Cell cycle is a tightly integrated process and is frequently aberrant in lung cancer. Cell cycle inhibitors have emerged as novel therapeutics, in anticipation of overcoming the unrestricted cell division and growth in lung cancer. Areas covered: In this article, we first address the potential roles of cell cycle proteins and cell cycle deregulation in the development of lung cancer. The review then provides an overview for several major categories of cell cycle inhibitors with particular attention to their tolerability and disease control in early phases of lung cancer trials. Expert opinion: Targeted agents against different components of cell cycle regulation, such as cyclin-dependent kinase, polo-like kinase, checkpoint kinase and aurora kinase, are currently in clinical development for lung cancer management. Their clinical benefits remain to be defined. When evaluated as single agents in lung cancer, cell cycle inhibitors are often associated with limited clinical activity and tolerable toxicities. The key challenges in the drug development are to understand resistance mechanisms and to identify predictive biomarkers that can potentially guide patient selection and optimize the utility of these targeted inhibitors.

AB - Introduction: Lung cancer remains to be the leading cause of cancer-related death worldwide. Treatment of lung cancer still poses a significant challenge. Cell cycle is a tightly integrated process and is frequently aberrant in lung cancer. Cell cycle inhibitors have emerged as novel therapeutics, in anticipation of overcoming the unrestricted cell division and growth in lung cancer. Areas covered: In this article, we first address the potential roles of cell cycle proteins and cell cycle deregulation in the development of lung cancer. The review then provides an overview for several major categories of cell cycle inhibitors with particular attention to their tolerability and disease control in early phases of lung cancer trials. Expert opinion: Targeted agents against different components of cell cycle regulation, such as cyclin-dependent kinase, polo-like kinase, checkpoint kinase and aurora kinase, are currently in clinical development for lung cancer management. Their clinical benefits remain to be defined. When evaluated as single agents in lung cancer, cell cycle inhibitors are often associated with limited clinical activity and tolerable toxicities. The key challenges in the drug development are to understand resistance mechanisms and to identify predictive biomarkers that can potentially guide patient selection and optimize the utility of these targeted inhibitors.

KW - Aurora kinase

KW - Cell cycle inhibitor

KW - Cyclin-dependent kinase

KW - Lung cancer

KW - Polo-like kinase

UR - http://www.scopus.com/inward/record.url?scp=84899451284&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899451284&partnerID=8YFLogxK

U2 - 10.1517/14656566.2014.902935

DO - 10.1517/14656566.2014.902935

M3 - Article

C2 - 24666387

AN - SCOPUS:84899451284

VL - 15

SP - 991

EP - 1004

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 7

ER -